BioSpace News Archive

Prometic Life Sciences Inc. is pleased to announce a new management structure to provide leadership to the Corporation and the appointment of Dr. Gary Bridger, Mr. Timothy Wach and Mr. Neil Klompas to the Board of Directors.

Takeda Pharmaceutical Company Limited announced that it has entered into agreements to divest its Xiidra® 5% product to Novartis and its TachoSil® Fibrin Sealant Patch to Ethicon as part of its strategy to focus on business areas core to its long-term growth and facilitate rapid deleveraging following its acquisition of Shire.

Fuse Medical, Inc., announced that it has filed its quarterly report on Form 10-Q for the first quarter ended March 31, 2019, with the United States Securities and Exchange Commission, on Tuesday, May 7, 2019.

Regen BioPharma, Inc. has received a number of inquiries regarding a potential reverse merger with another biotechnology related company.

Cortexyme, Inc. announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions.

Completion of recapitalization transactions and $75 million in gross proceeds secured from equity offering

St. Cloud Capital is pleased to announce a growth capital investment in AleraCare Holdings, LLC, a leading provider of both home and community-based healthcare and pharmacy services for high-need and medically complex populations.

Bloodworks Northwest (“Bloodworks”) is addressing a data privacy incident that involved personal information of some of its patients.

Titan Pharmaceuticals, Inc. will announce its first quarter 2019 financial results after market close on Wednesday, May 15, 2019.

Twist Bioscience Corporation announced the pricing of its underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $21.00 per share, before underwriting discounts and commissions.